osimertinib
astrazeneca
['adaura', 'nsclc', 'lcsm,(-blcsm)', 'sclc', 'osimertinib', 'aura ,(-laura)']
 presented the groundbreaking final overall survival analysis of the adaura trial using osimertinib for patients with stage 1b-3a and #egfr+ nsclc. this first-of-it's-kind study is likely to change the standard of care for resectable #nsclc #asco23 #lcsm 
LUNGevity, the nation’s leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer.